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Abstract
Background: The objective of the study was to analyse the evolution of Bordetella pertussis population and the influence of
herd immunity in different areas of the world where newborns and infants are highly vaccinated.
Methodology: The analysis was performed using DNA microarray on 15 isolates, PCR on 111 isolates as well as GS-FLX
sequencing technology on 3 isolates and the B. pertussis reference strain, Tohama I.
Principal Findings: Our analyses demonstrate that the current circulating isolates are continuing to lose genetic material as
compared to isolates circulating during the pre-vaccine era whatever the area of the world considered. The lost genetic
material does not seem to be important for virulence. Our study confirms that the use of whole cell vaccines has led to the
control of isolates that were similar to vaccine strains. GS-FLX sequencing technology shows that current isolates did not
acquire any additional material when compared with vaccine strains or with isolates of the pre-vaccine era and that the
sequenced strain Tohama I is not representative of the isolates. Furthermore, this technology allowed us to observe that the
number of Insertion Sequence elements contained in the genome of the isolates is temporally increasing or varying
between isolates.
Conclusions: B. pertussis adaptation to humans is still in progress by losing genetic material via Insertion Sequence
elements. Furthermore, recent isolates did not acquire any additional material when compared with vaccine strains or with
isolates of the pre-vaccine era. Herd immunity, following intensive vaccination of infants and children with whole cell
vaccines, has controlled isolates similar to the vaccine strains without modifying significantly the virulence of the isolates.
With the replacement of whole cell vaccines by subunit vaccines, containing only few bacterial antigens targeting the
virulence of the bacterium, one could hypothesize the circulation of isolates expressing less or modified vaccine antigens.
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Introduction
Bordetella pertussis, the agent of whooping cough, is strictly a
human pathogen. The incidence of this disease has been markedly
reduced in children thanks to high vaccination coverage with
vaccines containing inactivated bacterial suspensions, called
whole-cell pertussis (Pw) vaccines. Despite the use of efficacious
Pw vaccines, the disease still remains a serious public health
problem. In fact, with the introduction of childhood vaccination,
the circulation of the bacteria has decreased. In absence of natural
and vaccine boosters, the immunity of adolescents and adults
wanes over time and they become the main source of
contamination for infants too young to be vaccinated [1]. The
development of subunit vaccines, called acellular pertussis vaccines
(Pa), composed of purified detoxified bacterial proteins, allowed
the introduction of vaccine boosters for adolescents and adults,
now recommended in many developed countries. These boosters
are expected to reduce the transmission of the disease to infants
and persons at risk, thereby allowing a better control of the disease.
However, this may be achievable only if B. pertussis isolates are not
varying in terms of antigens and especially virulence.
Sequencing of the genome of a representative of each of the
three Bordetella species pathogenic for humans (B. pertussis and B.
parapertussis) and animals (B. bronchiseptica) was at the root of
numerous genomic studies and interspecies comparisons [2]. B.
bronchiseptica, the animal pathogen, is closely related to the
common bronchiseptica-like ancestor, and two independent events
in different B. bronchiseptica lineages probably have led to the
human-adapted B. pertussis and B. parapertussis [3]. Differences
between B. pertussis isolates are mainly due to mutations in
structural genes encoding toxins and adhesins, differential
expression of genes such as those encoding fimbrial proteins,
and gene reduction mostly mediated by IS elements [4–7].
Thanks to the availability of clinical isolates from the pre- and
post-vaccine era, B. pertussis population has been extensively
analysed during the last two decades [7]. Bacterial genome typing
using multilocus sequences typing (MLST), variable number
tandem repeat analyses (VNTR), and pulsed-field gel electropho-
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pertussis population [7]. However, it was possible, by using PFGE
and by comparing isolates from different areas of the world, as well
as isolates from the pre- and post-vaccine era, to differenciate B.
pertussis clinical isolates and to classify them in a few (I to VII)
PFGE groups [8-11]. PFGE groups I, VI and VII are minor
groups composed of a few number of isolates. PFGE groups II and
III are composed of the Pw vaccine strains and clinical isolates that
predominated during the pre-vaccine era but can still be collected,
although in minority. PFGE Group V is composed of isolates that
predominated in Europe in 1996-1997. Of note, they could
already be collected in Europe in the 1960’s (Guiso, unpublished).
PFGE group IV is composed of isolates predominantly circulating
since a decade in areas of the world with a 40-year high Pw
vaccine coverage. This last group can be subdivided into different
sub-groups according to their PFGE profiles (alpha, beta, gamma),
the proportion of which varies by area [9,12,13]. We confirmed
this PFGE classification by using DNA microarray [4]. Common
Regions of Difference (RD) were found in the genome of isolates
belonging to the same PFGE group or subgroup: RD1 (from
BP0911 to BP0937) and RD2 (from BP1135 to BP1141) were
found to be absent in the genome of isolates of most PFGE groups
or subgroups but present in the genome of all isolates of PFGE
group II, among which one of the French vaccine strain, IM1414.
RD3 (from BP1158 to BP1176) was present in the genome of the
second French vaccine strain, IM1416, and of PFGE group III
clinical isolates collected before 1980. It is deleted, however, from
the genome of more recently collected PFGE group III isolates.
RD4 (from BP1948 to BP1966) was not present in the genome of
PFGE Group IV, subgroup b isolates [4]. Some of these RD were
also observed by Brinig et al. [5] and by analysis of the temporal
evolution of Finnish isolates [6] .
The main objective of the present study was to analyse, by using
DNA microarray, whether the loss of genes in Bordetella isolates was
specific either to a special area of the world or to certain PFGE
groups, or whether this represents a general feature of the recent
isolates circulating in vaccinated areas of the world. We also checked,
thanks to an approach that uses GS-FLX sequencing technology,
whether these currently circulating isolates have acquired any
additional genetic material, as compared to the sequenced genome.
Methods
DNA microarray hybridization
The DNA microarray used, representing 91% of the predicted
coding sequences of the sequenced B. pertussis reference strain
Tohama I, is similar to the one previously described [4]. We have
chosen 15 isolates from PFGE group IV, collected between 1982
and 2005. Purified genomic DNA of all isolates was labelled with
either Cy3- or Cy5-dCTP, pooled with labelled DNA of the
reference Tohama I strain, and hybridized onpre-treated slides.For
each sample, a dye-swap experiment was realised simultaneously.
After hybridisation, slides were washed with the appropriate buffers
and then scanned with the GenePix4000B device.
Microarray data accession number
Protocols of genomic DNA preparation, purification, labelling,
hybridization, as well as raw and normalized microarray data in
MIAME format are available at Array Express data repository
under accession number E-MEXP-1322.
PCR validations of microarray results
PCR validations of the DNA microarray results were performed
for the RD4 as previously described [4], not only on the DNA
from the 15 isolates analysed by DNA microarray but also on
DNA from 60 isolates collected in France, 24 in Finland, 3 in The
Netherlands, 4 in Buenos Aires (Argentina), 4 in Alger (Algeria), 5
in Cincinnati (USA), 2 in Sweden, 4 in Germany, 5 in Saint-
Petersburg (Russia), as well as from 10 isolates of human B.
parapertussis and 10 of B. bronchiseptica. PCR were also run for the
RD1 and RD2 on some foreign isolates. A list of the isolates
analysed in this study is given in Table S1 (supplemental data).
The sequence of the primers for PCR validation is given in Table
S2 (supplemental data).
GS-FLX sequencing
The pyrosequencing of the genome of three isolates (FR0743,
FR3080 and FR3713), as compared to the sequenced genome of
the reference strain Tohama I, and the analysis of the sequences
were carried out by using a 454 GS-FLX NextGen sequencing
platform (Roche Diagnostics GmbH, Cogenics Genome Express).
Details of the protocols concerning genomic DNA preparation,
DNA library preparation, emulsion based-PCR and pyrosequen-
cing on GS-FLX are given in Methods S1.
Sequence analysis
The sequences produced for each sample were analyzed
separately. First, sequences were mapped on the reference genome
sequence Bordetella pertussis Tohama I, NC_002929, by using the
Newbler software V 1.1.02.15. Next, using a Cogenics script, all
strictly unmapped sequences were selected and assembled using
PHRAP software (version 0.960731, default parameters). Subse-
quently, the assembled consensus sequences and singletons were
mapped on the reference genome of B. parapertussis 12822
(NC_002928) and B. bronchiseptica RB50 (NC_002927) with the
SIM2 algorithm [14]. We defined a significant ‘‘map’’ as a
sequence alignment with more than 95% of similarity on 95% of
the experimental sequence length.
PCR validations of GS-FLX results
PCR validations of the results obtained thanks to the GS-FLX
pyrosequencing were performed for the RD11 to RD14 as
previously described (Caro V, Bouchez V, Guiso N, 2008. Is the
sequenced Bordetella pertussis strain Tohama 1 representative of the
species. In revision). A list of the isolates analysed in this study and
the primers used for PCR validation is respectively given in Table
S1 and Table S2 (supplemental data).
Results
Genomic representation of different RD identified by micro-
array for French and Finnish isolates are summarized in Figure 1.
They indicate that the genomic DNA from all tested isolates of the
PFGE group IV, whatever the subgroup, collected between 1982
and 2007 for French isolates and from 1982 to 2004 for Finnish
ones, do not possess RD1 and RD2, as compared with the
genomic DNA of the reference Tohama I. These RD, (RD1 from
BP0911 to BP0937 and RD2 from BP1135 to BP1141), are
identical to those observed previously [4,6]. However, the present
observations also indicate that RD4 (from BP1948 to BP1966),
which is present in 5 out of 8 genomes of isolates collected before
2000, is deleted in almost all isolates collected after 2001, whatever
the subgroup (Figure 1). PCR validations were performed on 5
different coding sequences within RD4. DNA microarray results
were confirmed and extended on 60 additional French isolates and
on 24 Finnish ones (Figure S1 of the supplemental data). Our
observations indicate that the loss of genetic material is continuing.
Indeed, significantly more than 78% of PFGE group IV isolates
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before 2000 (Chi2, p=8,21326E-06). The loss of RD4 is not
specific to these isolates of the PFGE group IV (Figure S1 of the
supplemental data), since RD4 is also absent in the DNA of one
French isolate of PFGE group III (collected in 2005), in the
genomic DNA of three French isolates of PFGE Group VI
(collected in 1995), and in the genomic DNA of 2 Finnish isolates
collected in 2004 and belonging to the PFGE group VII. All these
isolates originated from two countries, France and Finland, where
children were highly vaccinated.
Therefore, we tested through PCR validations the presence or
absence of RD4 in the genome of a few recent isolates collected
from other highly vaccinated areas that we previously analysed by
PFGE: 3 isolates from The Netherlands, 4 from Buenos Aires
(Argentina), 4 from Alger (Algeria), 5 from Cincinnati (USA), 5
from Saint-Petersburg (Russia), 2 from Sweden and 4 from
Germany. As shown in Figure S1 (supplemental data), RD4 was
found to be deleted in the genome of almost all isolates recently
collected, whatever the area of collection. Our results indicate that
RD4 deletion is not specific to any PFGE group or subgroup, and
that it does not represent a specificity of recent French or Finnish
isolates. The absence of RD1 and RD2 was also confirmed on
isolates of different origins (Figure S1 of the supplemental data).
Lastly, we screened for the presence of RD4 in the genome of
10 B. parapertussis and 10 B. bronchiseptica isolates (old and recent
ones). RD4 was present in all genomes tested, suggesting that this
deletion is specific to B. pertussis isolates recently circulating (Figure
S1 of the supplemental data).
As a complementary approach, we used the 454GS-FLX
sequencing system. One sequencing run was done simultaneously
for the reference strain Tohama I and for 3 French isolates of the
PFGE group IV: FR0743 (1999), FR3080 (2004) and FR3713
(2007). The latter isolate was chosen since it was collected from a
non vaccinated newborn who died from pertussis. It can be
considered to be representative of recent circulating isolates. Run
qualification, assembly and mapping characteristics data are
Figure 1. Genomic representation of different RD on B. parapertussis and B. pertussis sequenced reference strains and on B.
pertussis isolates RD identified with microarray (RD1, RD2 and RD4) and with GS-FLX (RD11, RD12, RD13 and RD14) were colored
according to their presence (yellow) and their absence (blue) on the genome of different B. pertussis isolates. Identified RD size is
proportional to their respective length and 10-fold increased in order to better visualize the regions on the genomes. RDs are located according to
their position on the B. parapertussis 12822 genome. (A). Circular representation of the genomes of B. pertussis Tohama I (black internal thick line)
and of B. parapertussis 12822 (green external thick line) (B). Circular representation of the genomes of B. parapertussis 12822 and of B. pertussis
isolates analyzed by microarray and harbouring RD4 (orange internal thick line) (C). Circular representation of the genomes of B. parapertussis 12822
and of B. pertussis isolates analyzed by microarray and not harbouring RD4 (purple internal thick line).
doi:10.1371/journal.pone.0002437.g001
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analysed, positive wells represented more than 96% of the total
and the more representative length of the sequence obtained was
between 240 and 250 nucleotides. Quality filters were applied on
the data to eliminate bad quality or usefulness sequences. Passed
filter wells for each genome was relatively homogeneous and
represented from 20.1Mb for FR3713 to 28.5 Mb for FR743,
which corresponds approximately to a fivefold recovery when
considering a genome size of 4 Mb for B. pertussis. Concerning GS
de novo assembly characteristics data for contigs greater than 500
bases, results are homogeneous for the 4 isolates, with an average
of 1500 contigs each. After mapping the B. pertussis Tohama I
reference strain, we can observe 44 non-mapping sequences
(representing approximatively 2 kb) for the control BPSM, vs more
than 1000 (representing approximatively 50 kb) for the 3 clinical
isolates tested. Those sequences were assembled and mapped to
the two reference genomes of B. parapertussis and B. bronchiseptica.
Around 45 kb separated in 4 regions (Figure 1) were found to
match B. parapertussis and B. bronchiseptica sequenced genome
(RD11 from BPP0529 to BPP0536, RD12 from BPP0822 to
BPP0827, RD13 from BPP0930 to BPP0949 and RD14 from
BPP4293 to BPP4301). The four regions were identified and PCR
validations were done as previously defined (Caro V, Bouchez V,
Guiso N, 2008. Is the sequenced Bordetella pertussis strain Tohama 1
representative of the species. In revision) (primers used are detailed
in Table S2 and results are presented in Figure S1 of the
supplemental data). PCR validations revealed that the 4 regions
representing 45 kb were present in the genome of both French
vaccine strains, IM1414 and IM1416, in the genomes of isolates
collected in the 60’s and of presently circulating isolates. Absence
of this region seems to be a specificity of the sequenced B. pertussis
genome. These results confirmed data obtained previously using
subtractive hybridization (Caro V, Bouchez V, Guiso N, 2008. Is
the sequenced Bordetella pertussis strain Tohama 1 representative of
the species. In revision). Furthermore, analysis and comparison of
the sequence data from the three isolates and from the reference
Tohama I strain revealed that the percentages of sequences
harbouring repeated structures found within genomes (such as
insertion sequence, IS481, but the nature of the repeated
sequences could not be verified) was increasing temporally. In
fact, this percentage is 2.2 for the Tohama I strain but 3.1 for the
isolate collected in 1999, 3.6 for the isolate collected in 2004 and
3.9 for the isolate collected in 2007.
Discussion
Recent bacterial pathogenomics studies revealed unexpected
features of bacterial evolution. There are 3 main forces that
shaped bacterial genome dynamics evolution: gene gain, gene loss
and gene changes [15]. Genomic studies on the Bordetella genus, as
the sequencing of the three major species pathogens for mammals,
showed that B. pertussis and B. parapertussis are independently
derived, host-restricted species that evolved from a B. bronchiseptica-
like ancestor which can infect many mammalian hosts but also can
live independently in the environment [2,3]. The evolution of the
three species occurred mainly by gene loss and gene expression
changes. The genome of the derived species, pertussis and
parapertussis, has a smaller size than their ancestor with a
considerable increase in the number of IS elements, pseudogenes
and many chromosomal rearrangements more particularly for B.
pertussis. It was also recently shown that allelic polymorphism at
homopolymeric tracts is common within the B. pertussis genome
[16]. This polymorphism could play a role in the adaptation of B.
pertussis to the Human host but could also play a role for evasion of
the immune system. In fact, B. pertussis is a vaccine preventable
disease. Since now more than 50 years a Pw vaccine is used in
some areas of the world with a high coverage for newborns and
children. The introduction of vaccination against Pertussis with Pw
vaccines has been associated with changes in B. pertussis
population. Isolates similar to Pw vaccine strains were probably
controlled by herd immunity since they are not predominant
anymore. The influence of Pw vaccination during several decades
on the characteristics of B. pertussis population has been previously
illustrated [7]. Indeed, we previously observed that when the same
vaccine was used during several decades with the same vaccine
coverage in two different areas of the world, similar isolates,
expressing similar virulence factors, remained circulating [8].
When similar, but not identical (i.e. containing strains expressing
different fimbriae), Pw vaccines were used, circulating isolates are
very similar but can still be differentiated, for example at the level
of fimbriae expression [12]. In many other studies, it was observed
that the proportion of isolates corresponding to the type of Pw
vaccine strains decreased over time, and that the isolates
remaining in circulation were those that exhibited differences to
the vaccine strains at the level of protein expression or mutation in
structural genes [7]. Furthermore, we previously showed that, in
France, the isolates currently circulating also possess less genetic
material than the isolates from the pre-vaccine era [4]. Similar
observation was recently published in Finland [6]. In the present
study, we have shown, using microarray analysis of the genome of
15 isolates and PCR validation of the microarray data on the
genome of 111 isolates, that the loss of genetic material is an
ongoing process. This loss is neither specific to France nor specific
to a particular PFGE group. RD had been previously described
between isolates from the pre- and post-vaccine era [4,6]: RD1
from BP0911 to BP0937 and RD2 from BP1135 to BP1141. We
have observed that the majority of isolates circulating since 2001
have also lost RD4 (from BP1948 to BP1966). We previously
observed (4) that RD4 deletion was only found in the genome of
PFGE group IVbeta isolates. Our present data show that this
deletion is present in the genome of almost all recent isolates
tested, whatever the PFGE group (III, IV, VI, VII). The RD4 is
composed of 17 ORFs that include 4 pseudogenes and 12 genes
encoding proteins involved in: ABC transport and in branched-
chain amino-acid transport; a putative ferri-siderophore receptor
bfrI; proteins involved in oxidoreduction reactions (oxidoreduc-
tase, monooxygenase); a transposase for IS1663; and a maleate
isomerase. We can assume that these genes are not essential to B.
pertussis survival inside its human host.
In parallel, using GS-FLX sequencing approach, we have
shown that recent isolates did not acquire additional material. We
have also confirmed that the sequenced genome is not represen-
tative of B. pertussis isolates (Caro V, Bouchez V, Guiso N, 2008. Is
the sequenced Bordetella pertussis strain Tohama 1 representative of
the species. In revision) a region of approximately 45 kb was
shown to be absent on the Tohama I genome but present in the
genome of the 3 tested clinical isolates. This region was still present
in the genome of all other clinical isolates of B. pertussis but also on
the B. parapertussis or B. bronchiseptica isolates tested, independently
of the year of collection. This sequencing approach allowed us to
observe that the number of IS elements is temporally increasing or
varying between isolates, indicating that the evolution of B. pertussis
is still in progress.
In our study, we confirm that the use of Pw vaccines has led to
the control of the isolates that were similar to the vaccine strains.
The predominant circulating isolates are different since they have
lost pseudogenes and genes not related to virulence. The loss of
genetic material is a dynamic process, not specific to France, but
B. pertussis Genomic Analyses
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been used since several decades to immunize children (Alger,
Buenos Aires, Finland, France, Saint-Petersbourg). This evolution
does not seem to apply to B. bronchiseptica and B. parapertussis.
However, these two species contain much less pseudogenes and
insertion sequences than B. pertussis. B. bronchiseptica is adapted to
many different mammal species but not really to humans and is
able to live in the environment. Even if it is sensitive to B. pertussis-
induced natural or vaccine immunity, this species is not
pathogenic for immunocompetent humans [17,18]. B. parapertussis,
that evolved from a bronchiseptica-like ancestor more recently than
B. pertussis, might not be submitted to B. pertussis immunity [19–21]
which implies that its evolution is not expected to be similar and
therefore needs to be studied.
Conclusion
Our data confirm that recent B. pertussis isolates circulating in
areas with high Pw vaccine coverage have less genetic material as
compared to isolates from the pre-vaccine era and those
circulating some years ago. The herd immunity induced by
vaccination has then induced a control of isolates similar to the
vaccine strains. Remaining isolates differ from the original ones by
loss of genetic material. Loss of genetic material, loss of gene
functions are one of the major mechanisms of specialization
already observed in many other pathogens, such as Yersinia,
Helicobacter, Salmonella, Pseudomonas [15,22,23]. Huge genome
reduction occurred between B. bronchiseptica and B. pertussis
genomes (from 5 to 3.8 Mb) and one may assume that this
reduction was simply a response to adapt to its new human host.
However, it may also reflect a lack of effective pressure for
maintaining these genes over long term evolution [24]. The
limited deletions observed in the genome of isolates currently
circulating as compared to those circulating during the pre-vaccine
era could be the result of modification in the functions involved in
host adaptation or a consequence of herd immunity that B. pertussis
has to face. The lost genetic material does not seem to be
important for virulence but could be important for recognition by
herd immunity. In fact, some deleted genes encode membrane
proteins, which could change the recognition by host cells
implicated in immunity. Will these isolates that are losing genetic
material not required for their survival in the human host escape
herd immunity? This is a major question, especially at a moment
where Pw vaccines are replaced by Pa vaccines. Answering this
question will necessitate further analyses. However, some obser-
vations can already give a piece of answer: Pw vaccines are
targeting the whole bacterium and they induce immunity able to
control isolates similar to the vaccine strains but not the recent
ones. This applies particularly to adolescents and adults whose
immunity is waning. By contrast, Pa vaccines are targeting the
virulence of B. pertussis. Virulence does not seem to have changed
over time, both in terms of toxins that are produced and the
pathogenicity as evaluated in animal or cellular models [25].
Therefore, it can be hypothesized that all types of isolates will be
controlled; especially since the vaccine coverage is increasing
thanks to the addition of boosters for adolescents and adults, which
is the case in France since 1998, and now also in developed
countries. One may argue that the antigens included in Pa
vaccines are different from the antigens displayed by the recent
circulating isolates [7], especially when considering pertussis toxin
and pertactin. However, Pa vaccines were shown to be efficacious
in countries where some isolates express different toxin and
adhesin [26]. No indication of ‘‘escape isolates’’ is provided from
the first epidemiological data in countries such as Sweden,
Germany and France that have been using Pa vaccines since only
ten years as a replacement of Pw. However, more time may be
needed to observe the circulation of such isolates. A question
remains whether ‘‘escape isolates’’ are expected to emerge, which
does not seem to be necessarily the case if coverage is increasing.
Nevertheless, one could expect an increased circulation of isolates
expressing less or no vaccine antigens, i.e. less virulent ones or
expressing modified isolates. In order to test this hypothesis
already proposed [27], surveillance must continue involving
standardized and specific diagnoses of the disease as well as
analysis and collection of circulating isolates. Such investigations
will help to adapt vaccine strategy and are underway in France.
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